Alosetron use drops dramatically with risk management.
Traynor
Kate
K
D016907:Adverse Drug Reaction Reporting Systems; D002243:Carbolines / Q000009:adverse effects* / Q000627:therapeutic use; D017091:Colitis, Ischemic / Q000139:chemically induced*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012308:Risk Management; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron